Preferred Events

4th Annual NGS Seminar – 2021 Digital Edition

14 September, 2021

16:00-19:00 CST | 10:00 AM-01:00 PM EST | 07:00-10:00 AM PST

The impact of COVID-19 has highlighted the biopharmaceutical industry’s need for fast & innovative solutions to accelerate the development and production of new therapies. Next-generation sequencing (NGS) is a performant, validated, and secure method that brings significant advantages.

We are happy to gather industry experts to discuss strategies around NGS adoption to answer the need for rapid and robust testing and ensure the product’s and patients’ safety. 

Digital Event

Why Participate

Meet experts to discuss NGS solutions to:

  • Improve QC testing of biologics
  • Reduce time to market
  • Share data with your peers
  • Improve patient safety

Who Should Register?

Biologics developers and manufacturers for:

  • Cell & gene therapy
  • Vaccines
  • Therapeutic proteins & antibodies
  • Blood and blood-derived products

Detailed Program 

Use of NGS to replace animal tests for the viral safety of biologics exclusive session:

Chairman: Horst Ruppach, PhD – Scientific & Portfolio Director, Biologics Testing Solutions at Charles River

  • The In Vivo Adventitious Virus Assay and Next Generation Sequencing: A Survey of the Biopharmaceutical Industry – Paul W. Barone, PhD | Director of the Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB), Massachusetts Institute of Technology
  • Evaluation of RNA Next Generation Sequencing to Replace In Vivo Tests for Assessing the Viral Safety of Cells Improve QC Testing of Biologics
    • Pascale Beurdeley, PhD | Chief Scientific Officer at PathoQuest
    • Marc Eloit, DVM, PhD – Founder and Scientific Advisor, PathoQuest | Head of “Pathogen Discovery Laboratory, Institut Pasteur
  • A Biomanufacturing Association’s Perspective of the ICH Q5(A) Guideline Revision – Marie Murphy, PhD | EFPIA Representative from ICHQ5A(R2) Guideline Revision EWG

Focus on the industry considerations session:

  • New technologies and new application around NGS technology
    • Colette Côte, PhD | Chief Portfolio Officer & US General Manager at PathoQuest
    • Pascale Beurdeley, PhD | Chief Scientific Officer at PathoQuest
  • Innovation Interactive Working session
?

1 study, 2 companies, 3 minutes, 4 experts to summarize this session

Our Speakers

EnglishFrenchGermanSpanish